Expertise in
19
conditions

Dr. Shobha R. Chitneni

Hematology
Hematology-Oncology Associates Of The Quad Cities PC
1351 Kimberly Rd Ste 100, 
Bettendorf, IA 
Accepting New Patients
44 Years of Experience
Expertise in
19
conditions
Hematology-Oncology Associates Of The Quad Cities PC
1351 Kimberly Rd Ste 100, 
Bettendorf, IA 

Overview

Shobha Chitneni is a Hematologist practicing medicine in Bettendorf, Iowa. She has been practicing medicine for over 44 years.

Dr. Chitneni is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, Essential Thrombocythemia, Large-Cell Immunoblastic Lymphoma, and Bone Marrow Aspiration.

She is actively involved in clinical research, participating in 11 clinical trials. Dr. Chitneni is currently accepting new patients.

Graduate Year

1982

Specialties

Hematology

Licenses

Specialist in IA

Hospital Affiliations

Trinity - Bettendorf
Mercyone Genesis Dewitt Medical Center
University Of Iowa Hospital & Clinics
Genesis Medical Center-Davenport
Genesis Hlth System Dba Genesis Mdl Ctr-Illini

Languages Spoken

English
Hindi
Telugu

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Sanford Health
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 14 Less Insurance Carriers -

Locations

Hematology-Oncology Associates of the Quad Cities PC
1351 Kimberly Rd Ste 100, Bettendorf, IA 52722

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
View 9 Less Clinical Trials
Similar Doctors
Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

UnityPoint Health Trinity Rock Island

2701 17th St, 
Rock Island, IL 
 (4.5 miles away)
309-779-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Costas Constantinou is a Hematologist practicing medicine in Rock Island, Illinois. Dr. Constantinou is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Monoclonal Gammopathy of Undetermined Significance (MGUS), Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, and Chronic Lymphocytic Leukemia (CLL). Dr. Constantinou is currently accepting new patients.

Expertise in
22
conditions
Dr. Mario B. Sy
Hematology
Expertise in
22
conditions
Dr. Mario B. Sy
Hematology
Referral may be required

Hematology-Oncology Associates Of The Quad Cities PC

1351 Kimberly Rd Ste 100, 
Bettendorf, IA 
 (0.1 miles away)
563-355-7909
Languages Spoken:
English, Filipino
See accepted insurances
Accepting New Patients

Mario Sy is a Hematologist practicing medicine in Bettendorf, Iowa. Dr. Sy is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Schnitzler Syndrome, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Richter Syndrome. Dr. Sy is currently accepting new patients.

Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required

University Of Iowa Stead Family Children's Hospital

200 Hawkins Dr, 
Iowa City, IA 
 (53.8 miles away)
319-335-4958
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Tomasson is a Hematologist practicing medicine in Iowa City, Iowa. Dr. Tomasson is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Acute Myeloid Leukemia (AML), Monoclonal Gammopathy of Undetermined Significance (MGUS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Tomasson is currently accepting new patients.

Frequently Asked Questions about Dr. Shobha R. Chitneni

How do I make an appointment with Dr. Shobha R. Chitneni?

You can book an appointment with Dr. Shobha R. Chitneni by calling their office at 563-355-7733. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Shobha R. Chitneni a top-rated expert for Monoclonal Gammopathy of Undetermined Significance (MGUS)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Shobha R. Chitneni is classified as an Distinguished expert for Monoclonal Gammopathy of Undetermined Significance (MGUS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Shobha R. Chitneni specialize in?

While Dr. Shobha R. Chitneni is a Hematology, they have specific expertise in Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, and Essential Thrombocythemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Shobha R. Chitneni accept my insurance?

Dr. Shobha R. Chitneni accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 563-355-7733 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chitneni's expertise for a condition
ConditionClose
    View All 18 Advanced Conditions
    View All 37 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile